drugset / Trial / NCT00614874

The Use of Rosiglitazone to Treat Asthma

NCT00614874 ↗

Phase 2 Completed 16 enrolled Creighton University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Asthma is a common chronic disease characterized by airway inflammation and bronchoconstriction. This study utilizes the drug rosiglitazone (Avandia)to treat the effects of airway inflammation in patients with asthma. The study will be conducted on 14 adult steroid naive patients with asthma. Patients with qualifying pulmonary function testing values will be eligible for enrollment. Enrolled subjects will be treated with rosiglitazone orally at 2mg dose for 4 weeks. Patients will be reassessed and dosing will increase in 4 week increments up to 8mg.

Timeline

Start
2008-12
Primary completion
2010-02
Completion
2010-03

Outcome

Met primary endpoint

registry analysis (superiority or other test); Rosiglitazone; p = 0.048; ANOVA; note: Comparison is between baseline and week 12 NCT00614874 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 8 mg Oral

Indications